Healthy menopausic women accepted to receive two consecutive estrogenic treatments: 1. ethinylestradiol 0.030 mg/d p.o. during 21 days; 2. a single dose of estradiol enantate (estra-1,3,5(10)-triene-3-ol-17 beta-heptanoate, one of the components of Perlutal or Topasel) 10 mg i.m. Both treatments were separated by a 1-month wash-out period, without any medicine. FSH, LH and prolactin serum levels were measured in each one of the subjects by radioimmunoassay before the beginning of each treatment and for at least 14 times during 31 days thereafter. A temporary decrease of the FSH levels and a temporary increase of the prolactin levels were induced by both treatments. In this respect the estradiol enantate effect was more precocious but the quality and the magnitude of the responses were similar among the two substances. The LH profile evolution was different: there was a decrease under estradiol enantate, but a very sharp increasing peak was observed on the 17th day under ethinylestradiol. By comparing the obtained results no significant statistical differences between the estrogenic potencies of the therapeutic schemes applied were found.

Download full-text PDF

Source

Publication Analysis

Top Keywords

estradiol enantate
16
estrogenic activities
4
estradiol
4
activities estradiol
4
enantate
4
enantate ethinylestradiol
4
ethinylestradiol compared
4
compared clinical
4
clinical level
4
level healthy
4

Similar Publications

Objectives: Human papillomavirus (HPV) is the leading cause of cervical cancer, with adolescent girls and young women (AGYW) in sub-Saharan Africa carrying a disproportionately high burden of infection. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but evidence remains inconclusive. This sub-study aimed to evaluate the impact of different hormonal contraceptives on HPV prevalence and genotype distribution in AGYW.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose testosterone replacement therapy (TRT) combined with finasteride offers benefits such as improved body composition, muscle strength, and bone density in older men, while mitigating the risk of prostate enlargement.
  • A pilot study involved 12 men with spinal cord injuries, demonstrating that TRT with finasteride significantly increased lean body mass and muscle size, alongside enhancing bone mineral density compared to a placebo.
  • Results suggest TRT + finasteride reduced fat mass and improved muscular strength, with measurable benefits observed as early as 6 months into the treatment, indicating its potential effectiveness for men with low testosterone post-injury.
View Article and Find Full Text PDF

Evaluating changes in body composition, bone mass, and metabolic profile in an animal model undergoing transfeminine hormone therapy and physical exercise.

Clin Nutr ESPEN

December 2024

Laboratory of Molecular and Translational Endocrinology (LEMT), Endocrinology Division, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/Unifesp), Rua Pedro de Toledo, N° 669, São Paulo, 04039-032, Brazil; Trans Care Outpatient Clinics; Núcleo de Estudos, Pesquisa, Extensão e Assistência à Pessoa Trans Professor Roberto Farina, Universidade Federal de São Paulo (Núcleo TransUnifesp), São Paulo, Brazil.

Background & Aims: Gender-affirming hormone therapy (GAHT) is essential for transgender individuals seeking body modifications. For transfeminine people assigned male at birth, GAHT typically involves a combination of antiandrogens and estrogens. Despite its importance, the scientific literature presents inconsistencies regarding the effects of these hormones on nutritional status, body composition, and biochemical markers.

View Article and Find Full Text PDF

Anabolic-androgenic steroids (AASs) impairment of reproduction has been reported. We investigated dose- and time-dependent effects of Nandrolone decanoate (ND) on reproductive system in comparison with Testosterone enanthate (TE). Male Wistar rats were administrated with 1, 3, and 9 mg/kg/weeks ND or 1 and 3 mg/kg/weeks TE for 8 weeks, and testicular phenotype and reproductive hormones were assessed at 4 and 8 weeks post-treatments.

View Article and Find Full Text PDF

The practice of hormone therapy is crucial in aligning secondary sex characteristics with the gender identity of transgender adults. This study examines the effects of a commonly used injectable hormone combination, specifically estradiol enanthate with dihydroxyprogesterone acetophenide (EEn/DHPA), on serum hormonal levels and self-reported satisfaction with breast development in transwomen. Our research focused on a retrospective longitudinal study involving a large cohort of transwomen evaluated between 2020 and 2022, comprising 101 participants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!